Cargando…

No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study

BRCA1/2 mutation carriers are offered gynaecological screening with the intention to reduce mortality by detecting ovarian cancer at an early stage. We examined compliance and efficacy of gynaecological screening in BRCA1/2 mutation carriers. In this multicentre, observational, follow-up study we ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hermsen, B B J, Olivier, R I, Verheijen, R H M, van Beurden, M, de Hullu, J A, Massuger, L F, Burger, C W, Brekelmans, C T, Mourits, M J, de Bock, G H, Gaarenstroom, K N, van Boven, H H, Mooij, T M, Rookus, M A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360170/ https://www.ncbi.nlm.nih.gov/pubmed/17426707 http://dx.doi.org/10.1038/sj.bjc.6603725

Ejemplares similares

Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up
por: Olivier, R I, et al.
Publicado: (2004)

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
por: Zaaijer, Leendert H, et al.
Publicado: (2016)

Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study
por: de Jonge, Marthe M, et al.
Publicado: (2021)

Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study
por: Harmsen, Marline G., et al.
Publicado: (2015)

High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors
por: Stroot, Iris A.S., et al.
Publicado: (2023)

A patient decision aid for risk‐reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing
por: Harmsen, Marline G., et al.
Publicado: (2017)

Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits
por: Schrijver, Lieske H, et al.
Publicado: (2022)

Cancer worry among BRCA1/2 pathogenic variant carriers choosing surgery to prevent tubal/ovarian cancer: course over time and associated factors
por: van Bommel, Majke H. D., et al.
Publicado: (2022)

Pain evaluation during gynaecological surveillance in women with Lynch syndrome
por: Helder-Woolderink, Jorien, et al.
Publicado: (2016)

The Effect of Risk-Reducing Salpingo-Oophorectomy on Breast Cancer Incidence and Histopathological Features in Women with a BRCA1 or BRCA2 Germline Pathogenic Variant
por: Stuursma, Annechien, et al.
Publicado: (2023)

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
por: Ligtenberg, M J L, et al.
Publicado: (1999)

Sentinel lymph node procedure in patients with recurrent vulvar squamous cell carcinoma: a proposed protocol for a multicentre observational study
por: van Doorn, Helena C., et al.
Publicado: (2022)

Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study
por: Heemskerk-Gerritsen, Bernadette A. M., et al.
Publicado: (2022)

BRCA1/2 testing rates in epithelial ovarian cancer: a focus on the untested patients
por: Lanjouw, Lieke, et al.
Publicado: (2023)

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers
por: van Sprundel, T C, et al.
Publicado: (2005)

Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study)
por: Terra, Lara, et al.
Publicado: (2021)

Cancer risk in DES daughters
por: Verloop, Janneke, et al.
Publicado: (2010)

President’s Address before the Chicago Gynæcological Society at the Second Annual Meeting
por: Byford, W. H.
Publicado: (1881)

EBCOG position statement – Simulation-based training for obstetrics and gynaecology during the COVID-19 pandemic
por: Zimmerman, Erin, et al.
Publicado: (2021)

Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis
por: van Bommel, Majke H D, et al.
Publicado: (2022)

Clinical outcome for BRCA1 and BRCA2 mutation carriers after contralateral prophylactic mastectomy
por: Schmidt, MK, et al.
Publicado: (2005)

High percentage of abnormal findings on TVU needs further discussion
por: Mourits, M J E, et al.
Publicado: (2006)

Application of sentinel nodes in gynaecological cancer therapy
por: Oonk, M.H.M., et al.
Publicado: (2013)

Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer
por: Kiely, B. E., et al.
Publicado: (2011)

Annual Meeting of the American Gynæcological Society
Publicado: (1878)

Robot assisted surgery during the COVID-19 pandemic, especially for gynecological cancer: a statement of the Society of European Robotic Gynaecological Surgery (SERGS)
por: Kimmig, Rainer, et al.
Publicado: (2020)

Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study
por: van Barele, Mark, et al.
Publicado: (2022)

Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers
por: Heemskerk-Gerritsen, Bernadette A. M., et al.
Publicado: (2019)

Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients
por: Bock, G H de, et al.
Publicado: (2001)

Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer
por: Verhoog, L C, et al.
Publicado: (2000)

Recommendations for a standardised educational program in robot assisted gynaecological surgery: Consensus from the Society of European Robotic Gynaecological Surgery (SERGS)
por: Rusch, P, et al.
Publicado: (2019)

Significant decrease of adenocarcinoma in situ not reflected in cervical adenocarcinoma incidence in the Netherlands 1989–2003
por: van de Nieuwenhof, H P, et al.
Publicado: (2008)

Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients
por: Papelard, H, et al.
Publicado: (2000)

Costs and Effects of Abdominal versus Laparoscopic Hysterectomy: Systematic Review of Controlled Trials
por: Bijen, Claudia B. M., et al.
Publicado: (2009)

Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness
por: de Bock, G H, et al.
Publicado: (2013)

HIF-1α Overexpression in Ductal Carcinoma In Situ of the Breast in BRCA1 and BRCA2 Mutation Carriers
por: van der Groep, Petra, et al.
Publicado: (2013)

Surveillance of women at high risk for hereditary ovarian cancer is inefficient
por: Oei, A L, et al.
Publicado: (2006)

Hemoglobin level predicts outcome for vulvar cancer patients independent of GLUT-1 and CA-IX expression in tumor tissue
por: van de Nieuwenhof, Hedwig P., et al.
Publicado: (2010)

Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap
por: McCuaig, Jeanna M, et al.
Publicado: (2018)

Surgical volume and conversion rate in laparoscopic hysterectomy: does volume matter? A multicenter retrospective cohort study
por: Keurentjes, José H. M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jquukn99quif85tht90mpmdrv7